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Abstract
Triglyceride accumulation in nonalcoholic fatty liver (NAFL) results from unbalanced lipid metabolism which, in the liver, is
controlled by several transcription factors. The Foxa subfamily of winged helix/forkhead box (Fox) transcription factors
comprises three members which play important roles in controlling both metabolism and homeostasis through the
regulation of multiple target genes in the liver, pancreas and adipose tissue. In the mouse liver, Foxa2 is repressed by insulin
and mediates fasting responses. Unlike Foxa2 however, the role of Foxa1 in the liver has not yet been investigated in detail.
In this study, we evaluate the role of Foxa1 in two human liver cell models, primary cultured hepatocytes and HepG2 cells,
by adenoviral infection. Moreover, human and rat livers were analyzed to determine Foxa1 regulation in NAFL. Results
demonstrate that Foxa1 is a potent inhibitor of hepatic triglyceride synthesis, accumulation and secretion by repressing the
expression of multiple target genes of these pathways (e.g., GPAM, DGAT2, MTP, APOB). Moreover, Foxa1 represses the fatty
acid transporter protein FATP2 and lowers fatty acid uptake. Foxa1 also increases the breakdown of fatty acids by inducing
peroxisomal fatty acid b-oxidation and ketone body synthesis. Finally, Foxa1 is able to largely up-regulate UCP1, thereby
dissipating energy and consistently decreasing the mitochondria membrane potential. We also report that human and rat
NAFL have a reduced Foxa1 expression, possibly through a protein kinase C-dependent pathway. We conclude that Foxa1 is
an antisteatotic factor that coordinately tunes several lipid metabolic pathways to block triglyceride accumulation in
hepatocytes. However, Foxa1 is down-regulated in human and rat NAFL and, therefore, increasing Foxa1 levels could
protect from steatosis. Altogether, we suggest that Foxa1 could be a novel therapeutic target for NAFL disease and insulin
resistance.
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Introduction
The Foxa subfamily of winged helix/forkhead box (Fox)
transcription factors comprises three members (Foxa1, Foxa2
and Foxa3) which play important roles in early mammalian
development and organogenesis. In postnatal life, the Foxa
transcription factors are also highly relevant because they play
key roles in controlling metabolism and homeostasis through the
regulation of multiple target genes in the liver, pancreas and
adipose tissue [1].
In the livers of adult mice, Foxa2 activity mediates fasting
responses, including fatty acid (FA) oxidation, ketogenesis,
gluconeogenesis and increased lipoprotein secretion, by activating
the expression of key genes of these pathways [2,3,4]. Foxa2 also
performs a crucial role in hepatic bile acid homeostasis and in the
prevention of cholestatic liver injury [5]. In the postprandial state
when insulin levels rise, Foxa2 is phosphorylated at Thr 156
through phosphatidylinositol 3-kinase/Akt signaling [6]. This
results in nuclear exclusion of Foxa2 [3] and inhibition of its
activity [7]. In hyperinsulinemic/obese mice, Foxa2 is perma-
nently inactive, which contributes to the development of hepatic
steatosis and insulin resistance [3].
Foxa1 and Foxa3 are not phosphorylated by insulin-signaling
cascades [6]. Nevertheless, Foxa3 also plays an important role in
liver metabolism as it regulates glucose homeostasis during a
prolonged fast through the maintenance of GLUT2 and
gluconeogenic gene expression [8].
In contrast to Foxa2 and Foxa3, the role of Foxa1 in liver
metabolism seems to be less critical. Foxa1 null mice develop a
phenotype characterized by progressive starvation, persistent
hypoglycemia, hypotriglyceridemia and neonatal mortality [9].
This phenotype, however, does not arise from liver dysfunction,
but develops because Foxa1 mediates glucagon gene expression
and insulin secretion in pancreatic cells [9,10]. The lack of a
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by Foxa2 and Foxa3 being able to compensate for the loss of
Foxa1 without gross alterations in gene expression of most Foxa
target genes. Similarly, mild hepatic phenotypes have been found
in Foxa2 and Foxa3 null mice [11,12].
To overcome this functional redundancy, we investigated the
role of Foxa1 in human hepatocytes and hepatoma cells by gain-
of-function experiments and found that Foxa1 is a potent inhibitor
of hepatic triglyceride (TG) synthesis and secretion. Moreover,
Foxa1 inhibits FA uptake and stimulates FA oxidation, ketone
body (KB) synthesis and energy dissipation in the mitochondria,
which indicates that Foxa1 can coordinate several transcriptional
responses to lower intracellular lipid levels in hepatocytes. We also
found that human and rat nonalcoholic fatty liver (NAFL) has a
reduced Foxa1 expression, which could promote the incorporation
of excessive circulating lipids into hepatocytes. Consistently, when
Foxa1 levels are high, steatosis significantly lowers.
Materials and Methods
Ethics Statements
Studies involving human samples or patients were performed in
agreement with the Declaration of Helsinki and with local and
national laws. The Human Ethics Committee of the respective
hospitals (Hospital La Fe Valencia and Hospital Santa Cristina
Madrid) approved the study procedures, and written informed
consent was obtained for all participants before inclusion.
Studies with laboratory animals followed the guidelines of, and
were approved by, the Animal Research Ethical Committee of the
University Hospital La Fe, Valencia (Approval ID: IIS-2010/
0023).
Patients and human liver bank
Part of this study comprised 17 nondiabetic patients with NAFL
who showed biopsy-proven steatosis (grade 1 or 2) without
necroinflammation or fibrosis; and 17 patients with asymptomatic
cholelithiasis from whom a liver biopsy was taken during
programmed laparoscopic cholecystectomy (normal liver was
confirmed). None of the 34 patients drank more than 20 g of
alcohol per day and none showed evidence of viral infections.
The Human Liver Bank of the Hospital La Fe-CIBERehd
(SPAIN) is a collection of donor livers which are primarily assigned
to liver transplantation but, due to failings in some of the inclusion
criteria (e.g. steatosis) they are donated to research.
Animals
Adult male OFA rats from Charles River (Barcelona, Spain)
were housed two per cage and acclimatized to laboratory
conditions for 7 days (12-hour light-dark cycle, 21–25uC, 30–
70% humidity, woodchip bedding). Rats were fed ad libitum for 7
weeks with either a methionine- and choline-deficient (MCD) diet
or standard isocaloric chow (#A02082002B and #A02082003B,
Research Diets INC. New Brunswick, NJ). Livers were perfused
and frozen in liquid N2.
Isolation and culture of human hepatocytes and cell lines
Human hepatocytes were isolated from nonsteatotic biopsies (1–
4 g) using a two-step perfusion technique [13]. Liver samples were
obtained in conformity with the rules of the Hospital’s Ethics
Committee. None of the donors (7 men and 6 women aged
between 22 and 74) were regular consumers of alcohol or of other
drugs, and were not suspected of harboring any infectious disease.
Cells were cultured in serum-free Williams/Ham’s F-12 (1/1, v/v)
medium (Gibco BRL, Invitrogen, Barcelona, Spain), supplement-
ed with 5 mM glucose, 0.2% bovine serum albumin, 0.01 mM
insulin and 0.01 mM dexamethasone.
HepG2 cells (ATCC HB-8065, Rockville, MD) were cultured in
Ham’s F-12/Leibovitz L-15 (1:1, v/v) medium (Gibco BRL,
Invitrogen, Barcelona, Spain), supplemented with 7% newborn
calf serum and 2 mM L-Glutamine. When incubated with FA,
HepG2 were cultured in the same serum-free medium as human
hepatocytes. In addition, culture media were supplemented with
50 U/ml penicillin and 50 mg/ml streptomycin.
To induce fat accumulation, cultured cells were exposed to
oleate and palmitate (2:1 ratio) (Sigma-Aldrich, Madrid, Spain), in
serum-free culture medium containing 1% FA-free BSA (Sigma-
Aldrich, Madrid, Spain). To assess the effect of PKC activation,
cells were exposed to 160 nM Phorbol 12-Myristate 13-Acetate
(PMA, Sigma-Aldrich, Madrid, Spain). Cells were also treated
with 200 nM Go ¨-6976 or 1 mM Ro-318220 as PKC inhibitors
(Sigma-Aldrich, Madrid, Spain). When both PKC activator (PMA)
and inhibitors (Go ¨-6976 or Ro-318220) were studied, inhibitors
were added to cultures 1 h before the activator.
Development of an adenoviral vector encoding human
Foxa1
The shuttle plasmid pAC-Foxa1 was constructed by ligation of
Foxa1 cDNA (kindly provided by Dr R Bort, UHE-La Fe,
Valencia, Spain) pre-digested with EcoRI-BamHI into the
adenoviral vector pAC/CMVpLpA [14]. This plasmid and the
pJM17 containing the dl309 adenovirus-5 genome, were co-
transfected into 293 with FuGENE HD Transfection Reagent
(Roche Applied Sciences, Barcelona, Spain). The homologous
recombination between these two plasmids resulted in a
replication defective virus (Ad-Foxa1), which was plaque-cloned,
amplified and purified, with the Vivapure AdenoPACK TM100
Kit from Sartorius (Goettingen, Germany), into a high-concen-
tration stock of 2.4610
7 plaque-forming units (PFU)/ml [14].
Human hepatocytes and HepG2 cells were infected with Ad-
Foxa1 or an insertless adenoviral vector (Ad-Control) for 24 h at a
multiplicity of infection (MOI) ranging from 1 to 36 PFU/cell.
Thereafter, cells were washed and fresh medium was added. At
48 h post-transfection cells were harvested and analyzed. Adeno-
viral vectors achieved nearly 100% transfection efficiency as
assessed by Ad-LacZ infection and b-galactosidase staining [14].
Biochemical functional assays
The neutral lipid content of cultured cells was determined
fluorometrically by Nile Red staining with a SpectraMAX
GeminiXS Fluorometer as described elsewhere [13]. To correct
potential variations in cell number, the DNA content was
determined in the same well/plates by Hoechst 33258 staining
(Sigma-Aldrich, Madrid, Spain).
The spectrophotometric assay of acyl-CoA oxidase (ACOX)
activity was based on the determination of H2O2 production,
which was coupled to the oxidation of 2,7-dichlorofluoroscein
diacetate in a reaction catalyzed by exogenous peroxidase [15,16].
Homogenates from infected HepG2 cells were sonicated in
phosphate potassium buffer 60 mM (pH 7.4) and centrifuged to
eliminate cell debris. The assay mixture (1 ml) containing 60 mM
phosphate potassium buffer (pH 7.4), 0.02% Triton X100,
0.6 mg/ml BSA, 40 mM aminotriazole, 0.05 mM 2,7-Dichloro-
fluoroscein diacetate, 0.015 mM FAD and 50 mg horseradish
peroxidase type II (all compounds from Sigma-Aldrich, Madrid,
Spain) was incubated with 100 mg of homogenate in the dark for
5 minutes. After this time, 30 mM of palmitoyl-CoA was added or
not to the mixture and absorbance at 502 nm was measured every
6 seconds during 2 minutes.
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medium with the Free Fatty Acid Quantification Kit and the beta-
Hydroxybutyrate (b-HB) Assay Kit, both from BioVision Research
Products (Mountain View, CA).
Homogenates from human liver were extracted with a
methanol-chloroform mixture and evaporated under nitrogen.
Total lipid and TG contents were measured in the lipid residue
using colorimetric kits from Spinreact (Gerona, Spain) based on
the vanillin-phosphoric acid reaction (#1001270) and the GPO-
POD enzymatic method (#1001311), respectively.
Reverse transcription and real-time quantitative PCR
Total RNA was extracted with TRIzol Reagent from Invitrogen
(Barcelona, Spain) and re-purified using the RNeasy Plus Mini Kit
from Qiagen (Madrid, Spain). Total RNA (1 mg) was reverse
transcribed as described [13] and real-time quantified using SYBR
Green I Master (Roche Applied Sciences, Barcelona, Spain) and
the appropriate primers (Table S1) in a LightCycler 480
Instrument. In parallel, two human housekeeping genes; porpho-
bilinogen deaminase (PBGD) and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH); were analyzed for normalization. In
each amplification, we included a reference calibrator cDNA
made from 18 nonsteatotic human livers (Human Liver Bank,
HLaFe-CIBERehd).
Relative mRNA levels were calculated with the LightCycler
Relative Quantification Analysis software. Briefly, the efficiency of
each PCR reaction was estimated from a serially diluted human
liver cDNA curve. This curve allows to determine the PCR
efficiency of each pair of primers. Based on these PCR efficiencies
and the cycle thresholds (Ct), the software calculates the relative
concentration of target and reference (PBGD or GAPDH) cDNAs
and their ratio.
For absolute quantification, amplicons were first confirmed by
agarose gel and purified with Wizard SV Gel and PCR Clean-up
System (Promega Biotech Iberica, Madrid, Spain). Next, the
amount of DNA was quantified with the Quant-it Picogreen
dsDNA Assay Kit (Molecular Probes, Invitrogen, Barcelona,
Spain), and properly diluted to be used as a reference standard
curve to interpolate and estimate the absolute amount of target
cDNA molecules in each sample.
Microarray expression analysis
Total RNA was purified from quadruplicate experiments in
HepG2 and cultured human hepatocytes infected with Ad-Foxa1
or control adenovirus (insertless Ad-pACC). mRNA expression
profiles were analyzed with the GeneChipH Human Gene 1.0 ST
Array (Affymetrix, Santa Clara, CA) as described [17]. Sample
preparation and microarray hybridization and scanning were
performed at the Gene Analysis Service (Central Research Unit
(UCIM), Faculty of Medicine, University of Valencia). Microarray
quality control assessment and data acquisition were performed
with the GeneChipH Operating Software (Affymetrix). Normali-
zation among the different microarray data files was performed by
robust multiarray analysis. Next, we applied a conservative probe
filtering (log2 expression value $5 in at least one sample). The
number of probes selected was 13128 in human hepatocytes and
14833 in HepG2 cells from the original probe set of 32320.
Differential mRNA expression was determined by using linear
models and empirical Bayes paired moderated t statistics. False
discovery rates were determined by following the Benjamini-
Hochberg procedure. The data from this study have been
prepared in compliance to MIAME guidelines and deposited in
the Gene Expression Omnibus (GEO) database with reference
numbers GSE30450 (human hepatocytes) and GSE30447
(HepG2).
Protein samples and immunoblotting analysis
Liver and cell homogenates, and culture media, were centri-
fuged at 130006g for 10 min at 4uC, and supernatants were
quickly stored frozen in aliquots at 280uC. Tissue and cell culture
samples were homogenized in T-PER and M-PER reagents from
Pierce (Fisher Scientific, Madrid, Spain). Protein concentration
was determined using the Protein Assay Kit from Bio-Rad
Laboratories (Madrid, Spain). Proteins were resolved by 12%
SDS-PAGE or 4–12% NuPage precast gels (Invitrogen, Barce-
lona, Spain), transferred to Immobilion membranes (Millipore
Iberica, Madrid, Spain) and incubated with an anti-ApoB
antibody (Rockland Immunochemicals, PA) or anti-Foxa1 anti-
bodies (sc-6553 and sc-101058, Santa Cruz Biotechnology, CA).
Blots were developed with horseradish peroxidase-labeled IgG
using an ECL kit from Amersham Biosciences/GE Healthcare
(Buckinghamshire, England). Equal loading was verified by
Coomassie Brilliant Blue or Ponceau S staining.
Olympus ScanR screening station
The high content screening imaging station Scan ˆR from
Olympus was used to analyze neutral lipid content, mitochondrial
membrane potential (MMP) and FA uptake, by using the specific
fluorescent probes BODIPY 493/503 (3.75 ng/ml), TMRM
(75 ng/ml) and C1-BODIPY 500/510-C12 (0.4 mg/ml), respec-
tively (Molecular Probes, Invitrogen, Barcelona, Spain). Cells were
loaded with the appropriate combination of fluorescent probes for
15–30 min and the medium was replaced with a buffered medium
(10 mM Hepes) for the analysis. The number of cells was
calculated from the number of Hoechst 33342 (1.5 mg/ml) stained
nuclei, and cell viability was determined by propidium iodide
(1.5 mg/ml) exclusion, which allows to perform functional
determinations only in the population of live cells. The 10X
objective was used to collect images for the distinct fluorescence
channels. Nine fields per well were acquired and analyzed by
simultaneous quantification of the different probe fluorescence
Figure 1. Foxa1 is more abundant than Foxa-2 and -3 in human
liver, but its expression declines in liver cell cultures. Foxa-1, -2
and -3 mRNA concentrations were measured in human livers (n=15),
human hepatocyte cultures (48 h of culture, n=8) and HepG2 cultures
(n=6) by real-time Q-RT-PCR. Foxa1 expression was assessed with two
different primer pairs (Foxa1-p1a n dF o x a 1 - p 2 ) .A b s o l u t ec D N A
quantification was performed by interpolation in DNA standard curves
with a known input concentration.
doi:10.1371/journal.pone.0030014.g001
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Statistical analysis
Statistical differences between group parameters were deter-
mined by the Student’s t-test and the Mann-Whitney U test.
Results
mRNA levels of Foxa factors in human liver and cultured
hepatic cells
Previous studies have suggested that Foxa1 is less abundant in
mouse liver than Foxa2 and Foxa3, despite the stronger gel
mobility-shift activity of Foxa1 with crude liver extracts [18].
However, the relative expression level of the three Foxas in human
liver has not yet been determined. We performed absolute mRNA
quantification and found that, in the human liver, Foxa1 is more
abundant than Foxa2 and 3 (Fig. 1). However in cultured human
hepatocytes and HepG2 cells, Foxa1 mRNA substantially
decreased (up to 15–40%), whereas Foxa2 and 3 mRNA levels
remained similar to liver levels (Fig. 1).
Over-expression of Foxa1 in cultured human liver cells
To circumvent the down-regulation of Foxa1 in cultured cells
and to overcome the functional redundancy among the three Foxa
factors, we developed a recombinant adenovirus encoding human
Foxa1. Transduction of cultured human hepatocytes and HepG2
cells with this adenovirus caused a significant, time- and dose-
dependent increase in Foxa1 mRNA and protein levels (Fig. 2A,
2B and 2C). The infective doses of Ad-Foxa1, selected from the
Figure 3. Foxa1 inhibits the expression of genes involved in TG and VLDL synthesis. Diagrams of TG (A) and VLDL (B) synthesis pathways
in the liver. Human hepatocytes (C) and HepG2 cells (D) were infected with Ad-Foxa1 or Ad-Control (12 MOI for human hepatocytes and 24 MOI for
HepG2) for 48 h, and the mRNA level of TAG and VLDL genes was measured by real-time Q-RT-PCR and normalized to the expression of the
housekeeping PBGD mRNA. Data represent the mean6SD of 4–5 independent experiments. * p,0.05; ** p,0.01; *** p,0.001 in relation to Ad-
Control infected cells. GPAT: glycerol-3 phosphate acyltransferase. AGPAT: 1-acylglycerol-3-phosphate-O-acyltransferase. DGAT: diacylglycerol
acyltransferase. MTP: microsomal triglyceride transfer protein. ACAT: acyl coenzyme A: cholesterol acyltransferase. APOB: apolipoprotein B.
doi:10.1371/journal.pone.0030014.g003
Figure 2. Adenovirus-mediated expression of Foxa1 in human liver cell cultures. HepG2 cells and cultured human hepatocytes were
infected with Ad-Foxa1 or Ad-Control, and Foxa1 or Foxa2 mRNA levels were measured by Q-RT-PCR and normalized to the expression of the
housekeeping PBGD mRNA. (A) Time-course analysis of Foxa1 mRNA after transduction of human hepatocytes and HepG2 cells with 5 and 24 MOI of
adenoviral vectors, respectively. Dose-response analysis of Foxa1 (B) and Foxa2 (D) in human liver cultured cells after different MOI of adenovirus for
48 h. Data represent the mean6SD of 3 independent experiments. (C) Protein levels of Foxa1 determined by immunoblotting (sc-6553 antibody) in
representative samples of human liver cultured cells after 12 (HH) or 24 (HepG2) MOI of adenovirus for 48 h (Ad-C: Ad-Control; Ad-F: Ad-Foxa1; HH:
human hepatocytes). Equal loading was verified by Ponceau S staining.
doi:10.1371/journal.pone.0030014.g002
Foxa1 Regulates Liver Lipid Metabolism and Storage
PLoS ONE | www.plosone.org 5 January 2012 | Volume 7 | Issue 1 | e30014Foxa1 Regulates Liver Lipid Metabolism and Storage
PLoS ONE | www.plosone.org 6 January 2012 | Volume 7 | Issue 1 | e30014dose-response experiments, were set at 5–12 MOI for human
hepatocytes and at 12–24 MOI for HepG2 cells.
Transduction of cultured cells with Ad-Foxa1 at the selected
MOI led to an increase in Foxa1 mRNA ranging from 7 to 21-fold
over the control level. This overexpression compensates for the
down-regulation of Foxa1 in cultured cells but exceeds the
averaged level in human liver.
We also evaluated the mRNA level of the other two Foxa family
members, Foxa2 and Foxa3, in response to Ad-Foxa1, and found
that human Foxa2 is significantly down-regulated by Foxa1, in both
human hepatocytes and HepG2 cells (Fig. 2D). The mRNA level of
Foxa3 was not substantially altered by Foxa1 (data not shown).
Gene expression profile of Foxa1-transfected human
hepatocytes and HepG2 cells
To determine the global impact of Foxa1 on human liver gene
transcription, microarray expression analyses were performed in
human hepatocytes and HepG2 cells transfected with Ad-Foxa1 or
Ad-Control. We performed quadruplicated independent experi-
ments and set the cut-off for the differentially expressed genes at a
q value (False Discovery Rate) of #0.05 and a fold change of 65/
3.
The results from cultured human hepatocytes revealed 1140
differentially expressed genes, of which 434 were up-regulated by
Foxa1 and 706 were down-regulated. The analyses in HepG2 cells
showed 1061 differentially expressed genes, of which 674 were up-
regulated by Foxa1 and 387 were down-regulated. The overlap of
the gene lists from human hepatocytes and HepG2 cells in Venn
diagrams was about 25%.
We next analyzed the overrepresented biochemical pathways in
our differentially-expressed gene lists by using the Consensus-
PathDB tool (Max Planck Institute for Molecular Genetics), which
was set at a p-value cut-off of ,0.01. We found more enriched
pathway-based sets in the lists of down-regulated genes, and among
them, several hepatic functions associated with FA, glyceropho-
spholipid, lipoprotein and bile acid metabolism. These pathways
were overrepresented in the gene lists of both human hepatocytes
and HepG2 cells suggesting that Foxa1 is likely to play a significant
regulatory role in lipid metabolism in the adult human liver.
Table S2 shows a list of lipid and carbohydrate metabolism
genes with differential mRNA expression in human hepatocytes
and HepG2 cells transfected with Ad-Foxa1 vs Ad-Control. Data
suggest that Foxa1 represses FA uptake, TG and VLDL synthesis,
FA synthesis/elongation/desaturation, and lipid droplet forma-
tion; whereas it induces FA catabolism and ketone body synthesis.
Foxa1 inhibits the expression of genes involved in TG
and VLDL synthesis
TG synthesis in the liver proceeds along a sequence involving four
reactions in the liver: 3 esterification reactions and 1 hydrolysis
reaction (Fig. 3A). Relative mRNA quantification by Q-RT-PCR
confirmed that most of the genes involved in this pathway (GPAT1:
glycerol-3 phosphate acyltransferase 1, AGPAT5 and 9: 1-acylgly-
cerol-3-phosphate-O-acyltransferase 5 and 9, and DGAT2: diacyl-
glycerol acyltransferase 2) were significantly repressed by Foxa1 in
human hepatocytes (GPAT1 and DGAT2, Fig. 3C, and AGPAT5
and AGPAT9, data not shown). GPAT1 and DGAT2 were also
down-regulated in Ad-Foxa1-transfected HepG2 cells (Fig. 3D).
The TG pathway is closely linked to the VLDL secretory
pathway (Fig. 3B). The synthesis of VLDL is substrate-driven, and
an elevated flux of free FA to the liver has hepatocytes primed to
channel FA into TG and VLDL [19]. Conversely, reduced TG
results in lower VLDL synthesis rates. Indeed, most of the genes
involved in VLDL synthesis (DGAT2, MTP: microsomal
triglyceride transfer protein, ACAT2: acyl coenzyme A: choles-
terol acyltransferase 2, and APOB: apolipoprotein B) were also
significantly down-regulated by Foxa1 in hepatocytes (Fig. 3C) and
in HepG2 cells (Fig. 3D). Altogether, our results suggest that Foxa1
can coordinately inhibit the key human genes involved in TG and
VLDL synthesis in the liver, which should result in the blockage of
TG accumulation and lipoprotein secretion by hepatocytes.
Foxa1 reduces steatosis and ApoB100 secretion in
cultured human liver cells
When primary human hepatocytes and HepG2 cells are
cultured in the presence of oleate and palmitate (2:1 ratio,
1 mM, 24 h), they accumulate intracellular lipids without
cytotoxic or apoptotic side effects [20]. The level of steatosis
attained is similar to that measured in human NAFL [20]. To test
the effect of Foxa1 on lipid accumulation and storage, cultures
were first transduced with Ad-Foxa1 and then exposed to FA. The
quantification of accumulated lipids by Nile Red fluorescence
demonstrated that Foxa1 significantly reduces steatosis in human
hepatocytes and HepG2 cells (Fig. 4A).
In order to confirm these results, we used an Olympus ScanˆR
Screening Station for automated analysis of cultured living cells and
the BODIPY 493/503 probe to stain intracellular neutral lipids.
Microphotographs in Fig. 4B show an increase in green
fluorescence by accumulated neutral lipids when cells were loaded
with1mM FA (24 h). However, transduction with Ad-Foxa1 largely
reduced this fluorescent signal in both HepG2 cells and human
hepatocytes. The quantification of the fluorescence intensities in
living cells once again revealed a significant inhibition of lipid
accumulation by Foxa1 (Fig. 4B), which reinforces the idea that this
transcription factor can reduce steatosis in human liver cells.
We also investigated the functional relevance of the inhibition of
VLDL genes by Foxa1. Immunoblotting analysis showed a strong
reduction in both intracellular and secreted (culture medium)
ApoB100 protein, when cells were infected with Ad-Foxa1
(Fig. 4C). These results were observed in both human hepatocytes
and HepG2 cells, and strongly suggest that VLDL synthesis is also
effectively inhibited by Foxa1.
Foxa1 reduces FA transport, increases FA catabolism and
uncouples mitochondria
What is the fate of excessive extracellular FA in Foxa1-
transfected cells? Two major possibilities may take place: less FA
transport into hepatocytes or/and higher FA catabolism rates.
Figure 4. Foxa1 reduces lipid accumulation and ApoB100 secretion in human liver cells. (A) Cultured human hepatocytes and HepG2
cells were transduced with Ad-Foxa1 or Ad-Control for 24 h and then exposed to FA (oleate: palmitate, 2:1). Twenty-four hours later, accumulated
lipids were quantified by Nile Red fluorescence. Data represent the mean6SD of 4–5 independent experiments. * p,0.05; ** p,0.01; *** p,0.001. (B)
Left panels: Representative microphotographs of living HepG2 cells and human cultured hepatocytes showing cytoplasmic neutral lipids stained with
BODIPY 493/503 (green), nuclei stained with Hoechst 33342 (blue) and death cell nuclei stained with propidium iodide (pink). Right panels:
Quantification of the BODIPY 493/503 fluorescent signal with the Olympus ScanR Screening Station in HepG2 cells (mean6SD, n=4) and in a
representative human hepatocyte culture. (C) Secreted (culture medium) and intracellular ApoB100 protein was analyzed by immunoblotting at 48h
after infection with adenoviral vectors. (M, fresh culture medium; Cont, non-infected controls; Ad-C, Ad-Control; Ad-F, Ad-Foxa1).
doi:10.1371/journal.pone.0030014.g004
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PLoS ONE | www.plosone.org 7 January 2012 | Volume 7 | Issue 1 | e30014Figure 5. Foxa1 decreases FA uptake. (A) Cultured cells were infected with Ad-Foxa1 or Ad-Control for 48h, and the mRNA level of the plasma
membrane fatty acid transporter protein 2 (FATP2) was measured by real-time Q-RT-PCR. (B) Human hepatocytes and HepG2 cells were infected with
Ad-Foxa1 for 24h and were then exposed to 0.2 mM FA (oleate: palmitate, 2:1) for an additional period lasting 16 h. The amount of non-consumed
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for FA uptake are: FABPpm, CD36/FAT, FATPs and caveolin
[21]. FABPpm and FAT/CD36 are membrane-associated FA-
binding proteins that facilitate FA translocation. However, FATPs
have been suggested to be the real FA transporters and vectorial
acylation has been proposed as the mechanism behind this [22].
We found that Foxa1-transfected cells express a 35–50% lower
level of the FA transporter protein FATP2 (Fig. 5A), an abundant
liver FATP and a major contributor to hepatic FA uptake [23].
We also performed functional assays to investigate whether a lower
FATP2 mRNA level results in decreased FA transport. Results
demonstrated that the percentage of non-consumed (residual) FA
in the medium were 1.7-2.0-fold higher in cultured human
hepatocytes and 1.2-1.7-fold higher in HepG2 cells, after Ad-
Foxa1 transduction (Fig. 5B), which indeed suggests a lower FA
uptake and usage. We wanted to confirm this finding by an
alternative approach and assessed the influence of Foxa1 on the
incorporation of a fluorescent FA analog (C1-BODIPY 500/510-
C12) during 15 min. Results demonstrated that Ad-Foxa1-
transfected HepG2 cells showed a 48–55% (human hepatocytes)
and 17–31% (HepG2) decrease in FA analog uptake with respect
to Ad-Control cells (Fig. 5C), thus reinforcing the idea that Foxa1
is able to reduce FA transport into hepatocytes.
Next, we intended to know whether Foxa1 also regulates FA
catabolism. We noted a significant up-regulation of a gene
involved in peroxisomal b-oxidation (CROT: carnitine O-
octanoyltransferase) in Ad-Foxa1-transfected human hepatocytes
and HepG2 cells (14-fold increase, Fig. 6A). In order to know if
peroxisomal b-oxidation was stimulated by Foxa1 we measured
the activity of acyl-CoA oxidase (ACOX), the first and rate-
limiting enzyme of this pathway. ACOX was proved to be a valid
measure of peroxisomal b-oxidation in homogenates of rat liver
[24]. We have assessed ACOX activity, based on H2O2-dependent
dichlorofluorescein oxidation [15,16] in cell extracts from HepG2
cells transfected with Ad-Control or Ad-Foxa1. Results demon-
strate that that ACOX activity is induced 2.4 fold when cells are
transfected with 24 MOI of Ad-Foxa1 (Fig. 6B) and indicate that
Foxa1 is able to stimulate peroxisomal FA b-oxidation.
In the context of FA catabolism, we have also found that Foxa1
activates ketogenesis through the induction of the mitochondrial 3-
hydroxymethyl glutaryl-CoA synthase (HMGCS2), the rate-
limiting enzyme of this pathway. HMGCS2 mRNA was induced
9-fold (Fig. 6A), and the level of ketone bodies (KB) increased 5.2-
6.3-fold in the culture medium of Ad-Foxa1-infected human
hepatocytes and 6.1-14.3 fold in HepG2 cells (Fig. 6C). Thus, our
results demonstrate that peroxisomal FA b-oxidation and
catabolism toward KB is enhanced by Foxa1.
Uncoupling protein 1 (UCP1) is not a gene with a constitutive
expression in the liver and, consequently, UCP1 mRNA
expression was very low in control human hepatocytes (cycle
threshold .34). However, UCP1 was induced by Foxa1 up to a
significant mRNA level (30-35-fold increase, Fig. 7A). If UCP1
function increases, mitochondria should be partially uncoupled
and the MMP reduced [25]. We measured the MMP in living cells
by using the Olympus ScanˆR Screening Station and the
fluorescent probe TMRM to find that Ad-Foxa1-infected cells
had a 20–25% reduction in HepG2 and a 4–10% decrease in
human hepatocytes (Fig. 7B). Microphotographs in Fig. 7C show
the decrease in red fluorescence (MMP) when cells are infected
with Ad-Foxa1. These results suggest that Foxa1 can stimulate the
leakage of protons into the mitochondrial matrix to dissipate
energy rather than allowing it to be captured in ATP.
Foxa1 expression decreases in human NAFL
A transcription factor that is able to coordinate a metabolic
response should be subjected to modulation by metabolic signals
and mediators. Foxa1 is not phosphorylated and inhibited by
insulin-signaling cascades. We investigated other possible meta-
bolic scenarios and found that the expression of this factor is down-
regulated in human NAFL.
We analyzed the expression of Foxa1 in a collection of human
livers from the Human Liver Bank HLaFe-CIBERehd, which
were classified as steatotic or nonsteatotic according to their lipid
content (Fig. 8A, see donors’ characteristics in Table 1 - left). We
measured the level of Foxa1 mRNA by Q-RT-PCR, and found a
significantly lower level in steatotic livers (68.8%, p,0.01) (Fig. 8B).
This down-regulation was also observed at the protein level, as
determined by immunoblotting of human Foxa1 in representative
control and fatty livers (Fig. 8C). To confirm these findings we also
measured Foxa1 mRNA levels in patients subjected to liver needle
biopsy (see patients’ characteristics in Table 1 - right). In
agreement with our previous results, we discovered lower Foxa1
mRNA levels in the group of patients with NAFL (67.1%, p,0.01)
(Fig. 8D).
Finally, we decided to know if the steatosis-induced repression of
Foxa1 occurs in NAFL animal models. Adult male OFA rats were
fed with either a methionine and choline deficient (MCD) diet or
standard isocaloric chow. The level of Foxa1 in steatotic rat livers
dropped to 50% (p=0.013) (Fig. 8E). Our results demonstrate that
human and rat NAFL is associated with a decrease in Foxa1
expression.
Foxa1 repression in human NAFL is likely mediated by
higher PKC activity/expression
The down-regulation of Foxa1 in steatotic liver could result
from different signaling pathways and mechanisms. One possibility
is hyperinsulinemia. NAFL favors insulin resistance and high
insulin plasma levels could cause Foxa1 down-regulation.
However, we did not observe Foxa1 down-regulation when
human hepatocytes and HepG2 cells were exposed to increasing
concentrations of insulin (data not shown). Other possibility is that
fat accumulation triggers intracellular signals or mediators that
cause Foxa1 down-regulation. Excessive FA delivery into hepato-
cytes results in accumulation of intermediate lipid metabolites such
as diacylglycerol, which can activate protein kinase C (PKC) that,
in turn, binds to the insulin receptor and inhibits its tyrosine kinase
activity leading to hepatic insulin resistance. We wanted to know if
the PKC signaling pathway could also lead to Foxa1 gene
repression. To assess this possibility, we exposed cultured cells to
the PKC activator phorbol 12-myristate 13-acetate (PMA) and
measured the level of Foxa1 mRNA (Fig. 9A) and protein (Fig. 9B).
The data obtained demonstrated that PMA represses Foxa1
expression in HepG2 cells.
In order to prove that the effect of PMA was mediated by PKC
activation, isoform specific PKC inhibitors were used. We found
that the general PKC-inhibitor Ro318220 was able to counteract
the repressive effect of PMA. However, Go ¨-6976, a more specific
(residual) free FA, expressed as the percentage of the initial amount in the culture medium, were determined with a specific kit. (C) The uptake of a
fluorescent FA analog (C1-BODIPY 500/510-C12) was measured in HepG2 cells and human cultured hepatocytes with an Olympus ScanR Screening
Station. Data represent the mean6SD of 4–5 independent experiments. * p,0.05; ** p,0.01; *** p,0.001 in relation to Ad-Control infected cells.
doi:10.1371/journal.pone.0030014.g005
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PLoS ONE | www.plosone.org 9 January 2012 | Volume 7 | Issue 1 | e30014Figure 6. Foxa1 increases FA catabolism and KB synthesis. (A) Cultured cells were infected with Ad-Foxa1 or Ad-Control for 48 h, and the
mRNA level of the mitochondrial 3-hydroxymethyl glutaryl coA synthase (HMGCS2, ketogenesis) and the peroxisomal carnitine O-octanoyltransferase
(CROT, b-oxidation) were measured by real-time Q-RT-PCR. (B) HepG2 were infected with Ad-Foxa1 or Ad-Control and 48 h after infection ACOX
activity was assayed spectrophotometrically in cell homogenates using palmitoyl-CoA as the substrate. Results were expressed as increments of
absorbance at 502 nm (DA)/min/mg of protein. (C) Human hepatocytes and HepG2 cells were infected with Ad-Foxa1 for 24 h and were then
exposed to 0.2 mM FA for an additional period lasting 24 h. The concentration of KB (b-HB, b-hydroxybutyrate) was determined in the culture
medium with a specific kit. Data represent the mean6SD of 4–5 independent experiments. * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0030014.g006
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2+-dependent: alpha, beta I/II
and gamma), did not affect the response of Foxa1 to PMA
(Fig. 9C). This points to the novel PKCs (Ca
2+-independent: delta,
epsilon, theta and nano) as the likely isoforms mediating the down-
regulation of Foxa1. We did not observe the repression of Foxa1
by PMA in human hepatocytes (n=2), where hepatocyte isolation,
culture conditions, medium composition and donor characteristics
may negatively influence the activation of PKC by PMA.
On the other hand, we found that the novel protein kinase C
epsilon (PKCe) mRNA was more abundant in human fatty livers
(153%, p,0.05) (Fig. 9D) and in NAFL patients (316%, p,0.01)
(Fig. 9E), suggesting that higher PKC expression and/or activity
(likely PKCe) could be associated with the down-regulation of
Foxa1 in human steatotic livers.
Discussion
No gross abnormalities have been observed in the livers of Foxa-
1, -2 or -3 null mice [9,11,12]. The three Foxas share a great
homology in the DNA-binding domain and in the recognition
sequences, and can compete for the same binding sites [26].
Consequently, it has been suggested that Foxa factors can
compensate each other, which hinders the use of loss-of-function
strategies. To circumvent this functional redundancy, transgenic
and adenovirus-infected mice have been generated [3,27,28,29].
However, most of these studies have been addressed to elucidate
the role of Foxa2 in bile acid [27], glucose [27,29] and lipid [3,28]
metabolism. Moreover, very few studies have attempted to
corroborate and determine the relevance of Foxa factors in the
human liver.
In the present study, we have investigated the regulation of
Foxa1 in human NAFL, and attempted to uncover the relevance
of this transcription factor in human hepatocytes and HepG2 by
gain-of-function experiments. Cell transfection with an adenoviral
vector encoding Foxa1 compensated for the decreased Foxa1
mRNA expression observed in cultured hepatocytes and HepG2
cells but also exceeded the level found in human liver. A potential
limitation of these overexpression studies is that mechanisms that
normally regulate gene transcription might be forced or
overwhelmed. Nevertheless, all our experimental evidence strongly
suggest that Foxa1 plays a key role in the control of lipid
metabolism in the human liver, which has not been previously
anticipated in animal models.
One important observation is the capacity of Foxa1 to
simultaneously inhibit the expression of most of the genes involved
in hepatic TG and VLDL synthesis pathways. Previous findings
demonstrated that elevated levels of Foxa2 activate the expression
of lipogenic genes (inducing steatosis) [28] and MTP (increasing
VLDL secretion) [4]. Our results demonstrate that Foxa1 can
activate the opposite response, which leads to decreased
intracellular lipids and ApoB100 secretion. The negative effect
of Foxa1 on DGAT2 is of particular relevance as knocking down
DGAT2 protects against fat-induced hepatic steatosis and insulin
resistance [30,31].
A second important and novel observation is the capacity of
Foxa1 to inhibit FA uptake by human hepatocytes. Our results
also suggest that this could be due to the repression of FATP2 by
Foxa1. FATP2 and FATP5 are the two major FATPs in the liver.
FATP2 knockdown by shRNA reduces FA uptake and hepatos-
teatosis in the face of continued high-fat feeding [23]. Previous
results with other Foxa members have not shown any inhibition on
FA transporters, instead an activating effect of Foxa2 on the FA
translocase FAT/CD36 has been reported [3].
A third important finding is the capacity of Foxa1 to activate FA
catabolism and increase energy expenditure. We observed a
Foxa1-dependent increase in CROT (peroxisomal b-oxidation)
and HMGCS2 (ketogenesis) mRNA levels, and in peroxisomal b-
oxidation and extracellular KB, which demonstrates enhanced FA
degradation. This observation is in line with previous findings
demonstrating that Foxa2 activates lipid catabolism and ketogen-
esis in the liver through the activation of a number of genes,
including HMGCS2 and CROT [3,7]. The considerable
induction of UCP1 by Foxa1 in human hepatocytes could also
contribute to its antisteatotic effect. UCP1 uncouples oxidative
phosphorylation and promotes the dissipation of cellular biochem-
ical energy. Forced UCP1 expression in the liver inhibits FA
synthesis with a concomitant enhancement of FA oxidation,
resulting in less fat in the liver [32]. We have shown that
endogenous UCP1 mRNA expression can be activated by Foxa1
in human hepatocytes, and that this associates with a lower MMP
potential which suggests a new mechanism to dissipate energy and
to reduce fat in the liver.
The molecular mechanism by which Foxa1 triggers the
transcriptional responses observed in this study remains to be
elucidated. However, the mechanism of repression by Foxa1 has
been attributed to an antagonistic interplay between Foxa1 and
Foxa2 [33]. It has been shown that both Foxa1 and Foxa2 are
activators of gene expression, but in the context of native
chromatin, Foxa1 is a poorer activator than Foxa2. Foxa1 does
not appear to act as a classic biochemical repressor but rather
exerts its negative effect by competing for the same cis-acting
promoter elements with the more efficient activator Foxa2 [33]. In
this context, we have observed that Foxa2 mRNA was down-
regulated by Ad-Foxa1 in human hepatocytes and HepG2 cells. A
lower Foxa2 expression along with the adenovirus-mediated
upregulation of Foxa1 can lead to an efficient exchange of Foxa2
by Foxa1 in the promoters of many lipid metabolism target genes,
leading to lower transcriptional activity.
Other major difference between Foxa1 and 2 is that plasma
insulin selectively inhibits Foxa2 by phosphorylation at Thr 156
[3,6,7], which is absent in the Foxa1 protein. Consequently, Foxa2
is inactive in the fed state and in insulin-resistant models [3],
whereas Foxa1 is constitutively active. Thus, the role of Foxa1
could be of particular relevance under both the fed and insulin-
resistant conditions, where Foxa2 remains inactive.
Moreover, our results also suggest that, in the human liver,
Foxa1 could be more abundant than Foxa2 and 3. Our results are
based on absolute quantitative RT-PCR with DNA standards. We
used DNA standards because they have larger quantification range
and greater sensitivity, reproducibility, and stability than RNA
standards [34]. However, potential differences in the efficiency of
the reverse transcription for each Foxa mRNA are not taken into
account with this experimental approach. Therefore, despite our
results suggest that Foxa1 is a major form of the Foxa family in
Figure 7. Foxa1 up-regulates UCP1 and decreases MMP. Cultured cells were infected with Ad-Foxa1 or Ad-Control (48 h), the mRNA level of
the mitochondrial uncoupling protein 1 (UCP1) was measured by real-time Q-RT-PCR (A), and the Mitochondrial Membrane Potential (MMP) was
measured using the TMRM probe in an Olympus Scan ˆR Screening Station (B). Data represent the mean6SD of 4–5 independent experiments. **
p,0.01; *** p,0.001. (C) Representative microphotographs of HepG2 cells and human cultured hepatocytes after 48 h of adenoviral transfection.
Cells were stained with TMRM (red) for mitochondrial membrane potential and Hoechst 33342 (blue) for nuclei.
doi:10.1371/journal.pone.0030014.g007
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PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30014Figure 8. Foxa1 expression is reduced in human and rat fatty liver. (A) Liver samples (100 mg) from the Human Liver Bank HLaFe-CIBERehd
were homogenized, extracted with methanol-chloroform and evaporated under nitrogen. Total lipids and TG were measured in the lipid residue
using colorimetric kits and livers were classified as fatty livers (closed circles) when total lipids were .600 mg/mg prot and TG.500 mg/mg prot
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approaches at both mRNA and protein level.
NAFL isveryfrequently associated with obesity and the metabolic
syndrome, and has been suggested to be a key triggering factor for
systemic insulin resistance [35]. High levels of a constitutively active
Foxa2 protein (Foxa2T156A), but not the wild-type protein, can
decrease liver steatosis [3], suggesting that Foxa2 could be a
pharmacological target for the treatment of NAFL and for
improving liver insulin sensitivity [36]. However, other studies have
shown that high levels of Foxa2 in transgenic mice cause postnatal
steatosis [28], which likely results from de novo lipid synthesis. In the
present study, we found that high levels of Foxa1 reduce steatosis in
humanhepatocytesandhepatomacells.Thus,Foxa1appearstobea
novel target for the therapy and prevention of human NAFL.
The expression analysis performed in the different human
sample groups and in rats has revealed that Foxa1 is down-
regulated in NAFL. This fact, along with the findings supporting
an antisteatotic role of Foxa1, led us to hypothesize that the down-
regulation of Foxa1 in NAFL is likely to increase uptake and
storage of excessive circulating FA into hepatocytes. Elucidating
the mechanism of this down-regulation could enable us to know
how to counteract this response and reduce steatosis. In this sense,
high-fat diet mice accumulate more liver diacylglycerol than wild-
type mice, which causes insulin resistance by activating PKCe,a
specific isoform of PKC [37,38]. Our data demonstrates that PKC
activation also represses Foxa1 in HepG2 cells. The use of specific
PKC inhibitors points to the novel PKCs as the likely isoforms
involved. Moreover, we demonstrate that human NAFLs have an
(n=20), or as nonsteatotic livers (open circles) when total lipids were ,400 mg/mg prot and TAG,300 mg/mg prot (n=30). (B) Total RNA was
purified from matching Liver Bank samples and the mRNA level of Foxa1 was determined by real-time Q-RT-PCR analysis. (C) Protein extracted with T-
PER from representative liver homogenates was analyzed by immunoblotting with a monoclonal antibody against human Foxa1 (sc-101058).
(D) Total RNA was also purified from NAFL (n=17) and cholelithiasis (n=17) patients’ liver biopsies and the mRNA level of Foxa1 was quantified by
real-time Q-RT-PCR. (E) Adult male OFA rats were randomized into two experimental groups (n=6 per group) and fed with either MCD or a standard
isocaloric diet for 7 weeks ad libitum. Total RNA was purified and the expression level of Foxa1 determined as explained above. Box plots represent
the 25
th, the median and the 75
th percentiles, a cross depicts the mean, whiskers indicate the 95
th and 5
th percentile, and dots represent outliers.
GAPDH mRNA was used for normalization.
doi:10.1371/journal.pone.0030014.g008
Table 1. Anthropometric and analytical parameters of steatotic and non-steatotic liver donors and patients.
Human Liver Bank
1 (Mean±SD) Human Liver Biopsies
2 (Mean±SD)
Non-Steatotic
(n=30; 14m 16f)
Steatotic
(n=20; 14m 6f)
Non-Steatotic
(n=17; 2m 15f)
Steatotic
(n=17; 8m 9f)
Age (years) 60618 47615* 50610 50613
BMI (kg/m
2)2 7 633 0 65* 27643 0 63*
Blood Tests
cGT (IU/L) 56669 56645 25617 37622
AST (IU/L) 44637 45625 17642 2 67*
ALT (IU/L) 33627 38630 16652 8 618*
ALP (U/L) 91642 103670 72626 75627
Quick’s value (%) 69623 80616 ND ND
Bilirubin total (mg/dL) 1.061.0 1.261.7 ND ND
Creatinine (mg/dL) 1.261.2 1.361.5 ND ND
Urea (mg/dL) 39619 33610 ND ND
Glucose (mg/dL) 178650 191689 90610 97614
Hemoglobin (g/dL) 16620 19626 ND ND
TG (mg/dL) ND ND 127650 161684
Chol-Tot (mg/dL) ND ND 200635 211644
Chol-HDL (mg/dL) ND ND 47610 47613
Insulin (mU/L) ND ND 6.262.7 10.766.3*
HOMA-IR ND ND 0.860.3 1.460.8*
Liver Tests
Tot Lip (mg/mg prot) 183681 12696509*** ND ND
TG (mg/mg prot) 93670 9196354*** ND ND
1Liver donors showed normal analytical blood test and, apart of the hepatic lipid concentration and the BMI, no major differences were found between steatotic and
non-steatotic.
2Patients with NAFL (grade 1 or 2) showed a higher BMI, a slight elevation of transaminases and a statistically higher insulin level and HOMA (Homeostasis Model
Assessment) index.
*p,0.05;
***p,0.001; m, male; f, female; ND, not determined.
doi:10.1371/journal.pone.0030014.t001
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PLoS ONE | www.plosone.org 15 January 2012 | Volume 7 | Issue 1 | e30014increased PKCe mRNA expression. This evidence supports the
involvement of novel PKCs in Foxa1 down-regulation, but the
specific isoform and pathway remains to be determined. Blocking
this specific PKC could prevent the down-regulation of Foxa1 in
human NAFL which, in turn, could help not only reduce
intracellular lipids, but alleviate insulin resistance in humans.
How does the activity of a kinase decrease expression of a gene?
In the regulatory systems for other genes, de novo synthesis of
repressors (inhibited by cycloheximide) is proposed to be the
mechanism of down-regulation by PKC [39]. In other studies, a
more direct effect of PKC on the phosphorylation of a repressor
has been suggested [40].
We conclude that Foxa1 can act coordinately in different
pathways to reduce hepatic lipid accumulation by inhibiting FA
transport and TG synthesis while stimulating FA catabolism and
dissipating surplus energy via enhanced UCP1 expression.
Moreover as Foxa1 is repressed in NAFL, its pharmacological
activation could counteract lipid deposition, and could prove
useful for the therapy and prevention of NAFLD and insulin
resistance.
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